Erlotinib Completed Phase 2 Trials for Neoplasms, Ovarian Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00130520Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer